NCT00146211

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Amarin Neuroscience Ltd · Industry
• Sex: All
• Age: 35 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Detailed description

Multi-center, double blind, placebo-controlled study with parallel groups of outpatients with early, symptomatic Huntington's disease. Participants will be randomized to receive 1 gram twice daily (2 gram/day total daily dose) of active study drug or placebo. The 6-month placebo-controlled phased will be followed by a subsequent 6-month open-label extension phase with all subjects receiving 1 gram twice daily (2 grams/day total daily dose) of active study drug.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	Ethyl-EPA (Miraxion™)

Timeline

• Start date: 2005-09-01
• Primary completion: 2007-08-01
• Completion: 2007-07-01
• First posted: 2005-09-07
• Last updated: 2007-12-27

Locations

41 sites across 2 countries: United States, Canada